


World Journal of *Hepatology*

World J Hepatol 2022 July 27; 14(7): 1269-1529



EDITORIAL

- 1269** Checkpoint inhibitor-induced hepatotoxicity: Role of liver biopsy and management approach
Bessone F, Bjornsson ES

REVIEW

- 1277** Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis
Liakina V, Strainiene S, Stundiene I, Maksimaityte V, Kazenaite E
- 1291** Hepatogenous diabetes: Knowledge, evidence, and skepticism
Kumar R, García-Compeán D, Maji T
- 1307** Small extracellular vesicles and liver diseases: From diagnosis to therapy
Tsuchiya A, Natsui K, Ishii Y, Koseki Y, Takeda N, Tomiyoshi K, Yamazaki F, Yoshida Y, Terai S
- 1319** Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
Spanu D, Pretta A, Lai E, Persano M, Donisi C, Mariani S, Dubois M, Migliari M, Saba G, Ziranu P, Pusceddu V, Puzzone M, Astara G, Scartozzi M

MINIREVIEWS

- 1333** Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings
Said ZNA, El-Sayed MH
- 1344** Alfapump® implantable device in management of refractory ascites: An update
Weil-Verhoeven D, Di Martino V, Stirnimann G, Cervoni JP, Nguyen-Khac E, Thévenot T

ORIGINAL ARTICLE

Basic Study

- 1357** Tissue pad degradation of ultrasonic device may enhance thermal injury and impair its sealing performance in liver surgery
Kajiwara M, Fujikawa T, Hasegawa S
- 1365** Regulation of PPAR- γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease
Li XY, Ji PX, Ni XX, Chen YX, Sheng L, Lian M, Guo CJ, Hua J

Clinical and Translational Research

- 1382** Transcriptome changes in stages of non-alcoholic fatty liver disease
Aljabban J, Rohr M, Syed S, Khorfan K, Borkowski V, Aljabban H, Segal M, Mukhtar M, Mohammed M, Panahiazar M, Hadley D, Spengler R, Spengler E

Retrospective Cohort Study

- 1398** Cardiac risk factors limiting survival to liver transplantation in patients with nonalcoholic fatty liver disease

Delicce M, Mauch J, Joseph A, Lyu R, Kren H, Bartow R, Ferchill D, Fares M, Wakim-Fleming J

Retrospective Study

- 1408** Differential distribution of gene polymorphisms associated with hypercholesterolemia, hypertriglyceridemia, and hypoalphalipoproteinemia among Native American and Mestizo Mexicans

Torres-Valadez R, Roman S, Ojeda-Granados C, Gonzalez-Aldaco K, Panduro A

- 1421** Effect of thrombocytopenia and platelet transfusion on outcomes of acute variceal bleeding in patients with chronic liver disease

Biswas S, Vaishnav M, Pathak P, Gunjan D, Mahapatra SJ, Kedia S, Rout G, Thakur B, Nayak B, Kumar R, Shalimar

Observational Study

- 1438** Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib

Sapena V, Iavarone M, Boix L, Facchetti F, Guarino M, Sanduzzi Zamparelli M, Granito A, Samper E, Scartozzi M, Corominas J, Marisi G, Diaz A, Casadei-Gardini A, Gramantieri L, Lampertico P, Morisco F, Torres F, Bruix J, Reig M

- 1459** Hepatobiliary phases in magnetic resonance imaging using liver-specific contrast for focal lesions in clinical practice

Fernandes DA, Dal Lago EA, Oliver FA, Loureiro BMC, Martins DL, Penachim TJ, Barros RHO, Araújo Filho JAB, Eloy da Costa LB, da Silva AMO, de Ataíde EC, Boin IFSF, Caserta NMG

- 1470** Efficacy and safety of COVID-19 vaccination in patients with cirrhosis

Ivashkin V, Ismailova A, Dmitrieva K, Maslennikov R, Zharkova M, Aliev S, Bakhitov V, Marcinkevich V

- 1480** Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma

Nakai M, Morikawa K, Hosoda S, Yoshida S, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Ohara M, Sho T, Suda G, Ogawa K, Sakamoto N

- 1495** Hepatitis C virus burden: Treating and educating people without prejudice

Merola E, Menotti E, Branz G, Michielan A, Seligmann S, Ratti A, Agugiaro F, Moser L, Vettori G, Franceschini A, Mantovani W, Pertile R, de Pretis G, Pravadelli C

Prospective Study

- 1504** Volumetric assessment of hepatic grafts using a light detection and ranging system for 3D scanning: Preliminary data

Katsanos G, Karakasi KE, Karolos IA, Kofinas A, Antoniadis N, Tsioukas V, Tsoulfas G

CASE REPORT

- 1512** Hepatitis B virus markers in hepatitis B surface antigen negative patients with pancreatic cancer: Two case reports

Batskikh S, Morozov S, Kostyushev D

- 1520 "Starry liver" - Von Meyenburg complex clinical case presentation and differential diagnosis discussion: A case report

Priadko K, Niosi M, Vitale LM, De Sio C, Romano M, De Sio I

RETRACTION NOTE

- 1528 Retraction Note: Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry

Khan M, Rauf W, Habib FE, Rahman M, Iqbal M

ABOUT COVER

Editorial Board Member of *World Journal of Hepatology*, Fan-Pu Ji, MD, PhD, Professor, Doctor, Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China. infection@xjtu.edu.cn

AIMS AND SCOPE

The primary aim of *World Journal of Hepatology* (*WJH*, *World J Hepatol*) is to provide scholars and readers from various fields of hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJH mainly publishes articles reporting research results and findings obtained in the field of hepatology and covering a wide range of topics including chronic cholestatic liver diseases, cirrhosis and its complications, clinical alcoholic liver disease, drug induced liver disease autoimmune, fatty liver disease, genetic and pediatric liver diseases, hepatocellular carcinoma, hepatic stellate cells and fibrosis, liver immunology, liver regeneration, hepatic surgery, liver transplantation, biliary tract pathophysiology, non-invasive markers of liver fibrosis, viral hepatitis.

INDEXING/ABSTRACTING

The *WJH* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 Journal Citation Indicator (JCI) for *WJH* as 0.52. The *WJH*'s CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Hepatology is 42/70.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yi-Xuan Cai; Production Department Director: Xiang Li; Editorial Office Director: Xiang Li.

NAME OF JOURNAL

World Journal of Hepatology

ISSN

ISSN 1948-5182 (online)

LAUNCH DATE

October 31, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Nikolaos Pyrsopoulos, Ke-Qin Hu, Koo Jeong Kang

EDITORIAL BOARD MEMBERS

<https://www.wjnet.com/1948-5182/editorialboard.htm>

PUBLICATION DATE

July 27, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Retraction Note: Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry

Mahim Khan, Waqar Rauf, Fazal-E- Habib, Moazur Rahman, Mazhar Iqbal

Specialty type: Chemistry, medicinal

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Chen X, China; Sira AM, Egypt

Received: November 2, 2021

Peer-review started: November 2, 2021

First decision: December 27, 2021

Revised: January 7, 2022

Accepted: March 16, 2022

Article in press: March 16, 2022

Published online: July 27, 2022



Mahim Khan, Waqar Rauf, Fazal-E- Habib, Moazur Rahman, Mazhar Iqbal, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering, Faisalabad 38000, Punjab, Pakistan

Corresponding author: Mazhar Iqbal, PhD, Professor, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering, Jhang Road, Faisalabad 38000, Punjab, Pakistan. hamzamgondal@gmail.com

Abstract

Retraction note: Khan M, Rauf W, Habib F, Rahman M, Iqbal M. Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry. *World J Hepatol* 2020; 12(11): 976-992 PMID: 33312423 DOI: [10.4254/wjh.v12.i11.976](https://doi.org/10.4254/wjh.v12.i11.976). The online version of the original article can be found at <https://www.wjgnet.com/1948-5182/full/v12/i11/976.htm>.

Key Words: Non-structural protein 3; Hepatitis C virus; Genotype 3a; Fluorescence resonance energy transfer

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: We have decided to retract the above article for further consideration due to some misunderstandings in communication.

Citation: Khan M, Rauf W, Habib FE, Rahman M, Iqbal M. Retraction Note: Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry. *World J Hepatol* 2022; 14(7): 1528-1529

URL: <https://www.wjgnet.com/1948-5182/full/v14/i7/1528.htm>

DOI: <https://dx.doi.org/10.4254/wjh.v14.i7.1528>

TO THE EDITOR

In this manuscript, actually our study focus was to develop fluorescence resonance energy transfer (FRET) assay through expression of non-structural protein 3/4a (NS3/4A) protease of HCV genotype 3a, followed by the evaluation of extract and targeted pure natural products. However, we mistakenly used the expression vector that contains co-factor NS4A from genotype 1a. But whole story was built and described on the use of NS4A sequence/expression vector from the genotype 3a. The amino acid sequences of NS4A of the genotype 1a (KKGSVVIVGRIVLSGK) is significantly different from the genotype 3a (KKGCVVIVGHIELGK) that lead to the variation in the activity of NS3/4A protease[1].

We checked NS3/4A activity with co-factors from both genotypes (1a and 3a) and found a clear variation in the proteolytic activity of NS3 protease when fused to its respective co-factor NS4A. As mentioned earlier, in the published manuscript, by mistake we supplemented the full-length NS3 and NS4A-fused NS3 protease with a peptide derived from the NS4A of a genotype 1a virus that led to wrong interpretation and conclusion. Now we found that NS4A of a genotype 3a virus is really compatible with NS3 protease (3a) and exhibited much higher protease activity than the NS4A of a genotype 1a virus. Subsequently, this led to difference in the inhibitory concentration values of inhibitors (extracts and natural products) screened through the FRET assay. This significant variation in the activity assay has altered the downstream inhibitory activities of extracts and natural products. Regrettably, this situation has forced us to retract our paper[2] to conduct more experimentation and make the major correction in data, before we can consider its rewriting and publication.

FOOTNOTES

Author contributions: Khan M wrote this retraction note.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Pakistan

ORCID number: Mahim Khan 0000-0003-3641-083X; Waqar Rauf 0000-0003-2853-3493; Fazal-E- Habib 0000-0002-4587-0312; Moazur Rahman 0000-0003-2892-1250; Mazhar Iqbal 0000-0002-8675-1125.

Corresponding Author's Membership in Professional Societies: The American Chemical Society, 30176895.

S-Editor: Xing YX

L-Editor: A

P-Editor: Xing YX

REFERENCES

- 1 **Beyer BM**, Zhang R, Hong Z, Madison V, Malcolm BA. Effect of naturally occurring active site mutations on hepatitis C virus NS3 protease specificity. *Proteins* 2001; **43**: 82-88 [PMID: 11276078]
- 2 **Khan M**, Rauf W, Habib F, Rahman M, Iqbal M. Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry. *World J Hepatol* 2020; **12**: 976-992 [PMID: 33312423 DOI: 10.4254/wjh.v12.i11.976]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

